Covid-19
| Product Name | Product No. | Product Details | Price | Reference | Data Sheet | Notes (Don't include in site) |
|---|---|---|---|---|---|---|
| HEK-ACE2-GFP cell line | CB-97100-203 | HEK293 was stably transfected with ACE2-GFP expression vector. The cell line has been tested positive for ACE2 antibody staining and GFP signal. It can be used for SARS and SARS-CoV-2 entry study. | $8,000.00 | Data Sheet | ||
| HEK293-ACE2- Stable cell Line | CB-97100-220 | HEK293 was stably transfected with human ACE2 expression vector. It can be used for SARS and SARS-CoV-2 entry study. | $8,000.00 | data sheet intentionally blank | ||
| pMLV-SARS2-Luciferase pseudovirus particles (614D), 5 ml | CB-97100-146 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $350.00 | Data Sheet | ||
| pMLV-SARS2-Luciferase pseudovirus particles-614G, 5 ml | CB-97100-146G | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $375.00 | A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent | Data Sheet 1 Data Sheet 2 | 2 data sheets for this product |
| pMLV-SARS2-Luciferase pseudovirus particles-453F (614G), 5 ml | CB-97100-151 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $400.00 | data sheet intentionally blank | ||
| pMLV-SARS2-Luciferase pseudovirus particles-501Y (614G), 5 ml | CB-97100-152 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $400.00 | data sheet intentionally blank | ||
| pMLV-SARS2-Luciferase pp-UK Mutant pseudovirus particles, 5 ml | CB-97100-153 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $425.00 | Data Sheet | ||
| pMLV-SARS2-Luciferase pp-SA Mutant pseudovirus particles, 5 ml | CB-97100-154 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $425.00 | Data Sheet | ||
| pMLV-SARS2-Luciferase puedovirus particles-222V (614G), 5 ml | CB-97100-155 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $400.00 | data sheet intentionally blank | ||
| pMLV-SARS2-Luciferase pp-Brazil Variant pseudovirus particles, 5 ml | CB-97100-157 | $425.00 | Data Sheet | |||
| pMLV-SARS2-Luciferase pp-India Variant pseudovirus particles, 5 ml | CB-97100-160 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $425.00 | Data Sheet | ||
| SARS-CoV-2-SA Variant Pseudovirus Particles-b-Lac, 5 ml | CB-97100-154b | $450.00 | Data Sheet | |||
| pMLV-SARS2-Luciferase pp-DELTA Variant pseudovirus particles, 5 ml | CB-97100-161 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $425.00 | Data Sheet | ||
| pMLV-SARS2-Luciferase pp-Omicron Variant pseudovirus particles, 5 ml | CB-97100-167 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $500.00 | Data Sheet | ||
| pMLV-SARS2-Luciferase pp-Omicron-BA.2 Variant pseudovirus particles, 5 ml | CB-97100-168 | For screening inhibitors to block SARS-CoV-2 infection; Validating neutralization antibodies. | $500.00 | Data Sheet |